These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6416 related articles for article (PubMed ID: 23460959)

  • 1. [Progress of anti-tumor study based on BRAF].
    Yan GR; Xu ZJ; Wang HY; Zhu WL
    Yao Xue Xue Bao; 2012 Dec; 47(12):1567-74. PubMed ID: 23460959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-Raf Inhibition in the Clinic: Present and Future.
    Fiskus W; Mitsiades N
    Annu Rev Med; 2016; 67():29-43. PubMed ID: 26768236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of resistance to anti-BRAF treatments].
    Charles J; Martel C; de Fraipont F; Leccia MT; Robert C; Busser B
    Ann Dermatol Venereol; 2014 Nov; 141(11):671-81. PubMed ID: 25442471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.
    Chapman PB
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
    Gibney GT; Zager JS
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
    Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
    Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF as a target for cancer therapy.
    Dienstmann R; Tabernero J
    Anticancer Agents Med Chem; 2011 Mar; 11(3):285-95. PubMed ID: 21426297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to BRAF-targeted therapy in melanoma.
    Sullivan RJ; Flaherty KT
    Eur J Cancer; 2013 Apr; 49(6):1297-304. PubMed ID: 23290787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF inhibitors: experience in thyroid cancer and general review of toxicity.
    Cabanillas ME; Patel A; Danysh BP; Dadu R; Kopetz S; Falchook G
    Horm Cancer; 2015 Feb; 6(1):21-36. PubMed ID: 25467940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.
    Spagnolo F; Ghiorzo P; Queirolo P
    Oncotarget; 2014 Nov; 5(21):10206-21. PubMed ID: 25344914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.
    Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Zárate R; Lozano MD; Zubiri L; Perez-Gracia JL; Martín-Algarra S; González A
    Clin Chem; 2015 Jan; 61(1):297-304. PubMed ID: 25411185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors.
    Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P
    Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.
    Bahrami A; Hesari A; Khazaei M; Hassanian SM; Ferns GA; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2162-2169. PubMed ID: 28407239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
    Shi H; Hugo W; Kong X; Hong A; Koya RC; Moriceau G; Chodon T; Guo R; Johnson DB; Dahlman KB; Kelley MC; Kefford RF; Chmielowski B; Glaspy JA; Sosman JA; van Baren N; Long GV; Ribas A; Lo RS
    Cancer Discov; 2014 Jan; 4(1):80-93. PubMed ID: 24265155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 321.